Ardelyx gains on Phase III hyperphosphatemia combination data

Ardelyx's tenapanor combination met all endpoints in the Phase III AMPLIFY trial for hyperphosphatemia, setting the stage for a planned 2020 NDA submission once it has long-term monotherapy safety data in hand.

Ardelyx Inc. (NASDAQ:ARDX) jumped 2.42 (71%) to $5.24 Tuesday on AMPLIFY's efficacy data for hyperphosphatemia in end-stage renal disease (ESRD) patients. The readout comes just ahead of the Sept. 12 PDUFA date for tenapanor in irritable bowel syndrome with constipation (IBS-C)...